Alnylam Pharmaceuticals Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: October 29, 2026 results vs estimates
Alnylam Pharmaceuticals Inc Forecast
Alnylam Pharmaceuticals Inc short-term momentum is strongly negative (up over 0 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is strongly negative (0 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 95.7% a year, a typical one-standard-deviation range is 150.56–197.44 over a week, 125.95–222.05 over a month and 7.5586–340.44 over a year. (Signals as of 1 Nov 2026.)
Alnylam Pharmaceuticals Inc Price Chart
Alnylam Pharmaceuticals Inc Factors
YoY −99.4%
YoY −74.3%
YoY −97.4%
YoY −94.5%
YoY −76.3%
YoY +464.4%
YoY +15,504.1%
YoY −59.9%
YoY +64.2%
YoY −75.4%
YoY −2.5%
YoY −2.6%
YoY +306.8%
YoY −93.7%
YoY −16.7%
YoY −41.5%
Alnylam Pharmaceuticals Inc fundamentals: income statement, balance sheet & cash flow
Alnylam Pharmaceuticals Inc reported revenue of $3.71bn and net income of $313.7m in FY2025, the year ended 31 December 2025 — revenue up 65.2% and net income up 212.8% on the prior year. Free cash flow was $465.4m. These figures are as reported in the filings, not restated: 24 fiscal years and 95 quarters of history, back to December 2002. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 3,713.9 | 2,248.2 | 1,828.3 | 1,037.4 | 844.3 |
| Cost of revenue | 677.2 | 323.4 | 310.4 | 168.8 | 140.1 |
| Gross profit | 3,036.8 | 1,924.9 | 1,517.9 | 868.6 | 704.1 |
| Research & development | 1,324.5 | 1,126.2 | 1,004.4 | 883.0 | 792.2 |
| Selling, general & admin. | 1,210.7 | 975.5 | 795.6 | 770.7 | 620.6 |
| Operating income | 501.6 | -176.9 | -282.2 | -785.1 | -708.7 |
| EBITDA | 631.4 | -178.8 | -258.2 | -926.6 | -661.6 |
| Interest expense | 252.6 | 141.9 | 121.2 | 156.0 | 143.0 |
| Pre-tax income | 323.2 | -377.4 | -433.5 | -1,127.0 | -852.1 |
| Income tax | 9.4 | -99.2 | 6.7 | 4.2 | 0.7 |
| Net income | 313.7 | -278.2 | -440.2 | -1,131.2 | -852.8 |
Download Alnylam Pharmaceuticals Inc fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.ALNY.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Alnylam Pharmaceuticals Inc
Explore MacroFinance macro & markets research and analysis.
Alnylam Pharmaceuticals Inc Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Alnylam Pharmaceuticals Inc; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Alnylam Pharmaceuticals Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Alnylam Pharmaceuticals Inc (United States)
Alnylam Pharmaceuticals Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Alnylam Pharmaceuticals Inc?
What is the latest Alnylam Pharmaceuticals Inc price?
Is Alnylam Pharmaceuticals Inc in an uptrend?
How volatile is Alnylam Pharmaceuticals Inc?
What factors affect Alnylam Pharmaceuticals Inc?
Which trading strategies trade Alnylam Pharmaceuticals Inc?
How are Alnylam Pharmaceuticals Inc returns analysed?
Where can I download free Alnylam Pharmaceuticals Inc historical data?
Free Alnylam Pharmaceuticals Inc historical data (last 10 years)
Browse or instantly download the last 10 years of Alnylam Pharmaceuticals Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ALNY.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 143.82 |
| 2026-11-19 | 147.82 |
| 2026-11-18 | 149.4 |
| 2026-11-17 | 156.5 |
| 2026-11-16 | 159.73 |
| 2026-11-13 | 165.04 |
| 2026-11-12 | 156.65 |
| 2026-11-11 | 159.85 |
| 2026-11-10 | 151.64 |
| 2026-11-09 | 156.61 |
About this stock
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.